Semaglutide reduces food noise by binding GLP-1 receptors in the hypothalamus, disrupting constant mental food preoccupation that drives compulsive eating

Semaglutide demonstrates significant efficacy in reducing binge eating episodes through GLP-1 receptor modulation, with clinical trials showing 40–60%

Semaglutide delivers 8–12% body weight reduction in 3 months at therapeutic doses. Here’s the clinical evidence, realistic timelines, and what impacts

Weight regain after semaglutide averages 10–15% within 12 months of stopping. Here’s what drives rebound and how medical supervision changes outcomes.

Semaglutide and statins can be safely combined under medical supervision — both address metabolic health but through different mechanisms requiring dosage

Semaglutide doesn’t replace thyroid medication but can affect thyroid function. Here’s what patients taking both medications need to know about safety and

Semaglutide maintenance dose typically stabilizes at 1.7–2.4mg weekly after 16–20 weeks of titration, balancing weight loss results with side effect

Cycling off semaglutide causes weight regain in most patients unless managed correctly. Learn safe discontinuation strategies, metabolic effects, and

Switching from semaglutide requires careful timing, washout periods, and dose alignment. Learn the medically sound approach to transitioning GLP-1